Translate Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Translate Bio, Inc. - overview
Established
2011
Location
Lexington, MA, US
Primary Industry
Biotechnology
About
Translate Bio, Inc. is a biotechnology company focused on developing messenger RNA (mRNA) therapeutics to treat diseases, leveraging innovative approaches in genetic medicine. Translate Bio, Inc. specializes in mRNA therapeutics, founded in 2011 and headquartered in Lexington, US.
The company has undergone strategic pivots and was acquired by Sanofi S. A. in a Trade Sale for USD 3. 2 billion.
The CEO is Rana Latif, who has a strong background in the industry. The firm has raised a total of USD 3. 2 billion, with the most recent deal occurring on 2019-09-19. Translate Bio, Inc.
focuses on mRNA therapeutics, crafting solutions aimed at treating various diseases. The company develops innovative therapies that harness the potential of mRNA technology, targeting unmet medical needs and offering promising avenues for treatment. In 2020, Translate Bio, Inc. reported a revenue of USD 138.
81 mn, with an EBITDA of USD -46. 05 mn, reflecting its ongoing investment in research and development within the biotechnology sector. Translate Bio, Inc. plans to leverage its recent acquisition by Sanofi S.
A. to expand its product offerings in mRNA therapies, targeting new disease areas by mid-2022. The recent funding of USD 3. 2 billion will be directed towards accelerating the development of its therapeutics pipeline and expanding into international markets.
Current Investors
Atlas Venture, SR One, Monsanto Company
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.translate.bio
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.